CNGB3 and achromatopsia: In addition to this trial, two other companies, MeiraGTx and Applied Genetic Technologies Corp (AGTC), started separate phase I/II clinical trials to examine their AAV therapies in both children and adult patients with CNGB3 and CNGA3 achromatopsia (MeiraGTx: NCT03001310, NCT03758404; AGTC: NCT02935517, NCT02599922).